Dr. Reddy’s expands collaboration with Amgen in India
Dr. Reddy’s Laboratories has expanded its strategic collaboration with Amgen to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis.
Under the terms of the collaboration, Dr. Reddy’s will commercialise XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.
In 2015, Dr. Reddy’s announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen’s Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India.
The collaboration leverages the capabilities of both companies, combining Amgen's innovative therapies with Dr. Reddy’s deep understanding of patient and physician needs in India.
Click on this link for more information.
